Author  
Place of duty  
Title   급성기 및 가속기 만성 골수성 백혈병에서 MCNU 단독요법 및 복합항암화학요법의 치료효과 ( Chemotherapy Including MCNU for the Treatment of Terminal Phase Chronic Muelogenous Leukemia )
Publicationinfo   1993 Jan; 025(02): 247-252.
Key_word   CML, MCNU
Full-Text  
Abstract   A 66% response was obtained in 30 evaluable patients in the terminal phase CML(AP: 19, BC; 11) using MCNU single or combination chemotherapy(MCNU, Etoposide, and Hydroxyurea). 26 %(5/19 cases) of responses were complete in accelerated pahse and 9%(1/11 cases) in blastic crisis A 47%(9/19 cases) partial response was obtained in accelerated phase and 45%(5/11 cases) in blastic phase. Overall median survival of reeponder wes 8 months(range: 4-11 months). Side effects were minimal and there were no treatment assaciated mortality and severe bone marrow failure. these results suggest that MCNU is a safe and valuable addition to the therapeutic repertoire for the control of terminal phaee CML and patients getting a chance of secondary chronic phase might be indicated for allogenic allogenic bone marrow transplantation.
저 자   김동욱(Dong Wook Kim),김희제(Hee je Kim),김희열(Hee Je Kim),유기동(Ki Dong Yu),이종욱(Chong Wook Lee),진종률(Jong Youl Jin),한치화(Chi Wha Han),민우성(Woo Sung Min),박종원(Chong Won Park),김춘추(Choon Choo Kim),김동집(Dong Jip Kim)